Law firm analysis finds no lawful compounding pathway for retatrutide

Eli Lilly filed six federal lawsuits on August 12, 2026 against businesses it accuses of illegally selling retatrutide, its experimental "triple-agonist" obesity drug that has not been approved by the FDA or any regulator worldwide ^[1]. In an August 18 analysis, attorneys at the law firm Frier Levitt concluded that, unlike the earlier fights over compounded semaglutide and tirzepatide, this one has "no gray zone": retatrutide cannot lawfully be compounded today because it is not a component of an FDA-approved drug, does not appear on the FDA's list of bulk drug substances eligible for compounding, and lacks a USP or NF monograph ^[1].

What the lawsuits target

The six cases were filed in four different federal district courts in Texas and name four "research-use-only" (RUO) peptide sellers, a medical spa and a compounding pharmacy ^[1]. Lilly asks each court for a permanent injunction barring the defendant from making, marketing, distributing, dispensing or selling any product containing or purporting to contain retatrutide, plus disgorgement of profits and attorney's fees ^[1].

According to the analysis, the RUO sellers labeled their products for laboratory research — a designation not meant for human use — while marketing them in ways Lilly alleges were aimed at consumers ^[1]. The complaint against the med spa, Aesthetic Envy, alleges it openly advertised a "Triple G" retatrutide product on its website and social media, and the complaint against the pharmacy alleges it sold retatrutide to medical spas and providers ^[1]. Lilly's filings say these businesses "are not practicing medicine; they are selling illegal drugs," and argue that because the products are unregulated they may be fake, impure or mis-dosed ^[1].

Most of the claims are brought under state unfair competition and consumer protection statutes in Texas, Tennessee, Washington, North Carolina, South Carolina, Colorado, Connecticut and Alaska, not patent law ^[1]. The only federal false-advertising claim under the Lanham Act is against the med spa ^[1]. Frier Levitt notes the federal Food, Drug, and Cosmetic Act does not create a general private right of action, so a competitor cannot sue directly over misbranding or unapproved-drug violations ^[1].

The six suits are a small slice of a larger effort. Lilly reports it has referred more than 200 individuals and entities to the FDA, the Justice Department, state attorneys general, law enforcement and licensing boards, and has flagged more than 14,000 websites, ads and social media listings offering retatrutide worldwide ^[1]. Separately, Becker's reports Novo Nordisk has filed 130 federal lawsuits and five National Advertising Division challenges over GLP-1 copies, while Lilly has filed dozens of federal suits and at least five NAD challenges; the FDA has issued more than 100 warning letters over misbranded compounded GLP-1 claims in the past year ^[2].

Why it matters for patients

Retatrutide is in Phase 3 trials, and Lilly does not expect to submit an FDA application until 2027 ^[1]. That means the only legal routes to the drug in the United States right now are Lilly-sponsored clinical trials or, in narrow circumstances, the FDA's expanded access framework — it cannot legally be sold to any patient ^[1]. The FDA has stated that retatrutide "cannot be used in compounding under federal law" ^[1].

This is different from the compounded semaglutide and tirzepatide market. Those molecules were FDA-approved drugs subject to shortage-based compounding exceptions under Sections 503A and 503B, so the disputes were largely about whether a shortage still existed and whether a compounded version was sufficiently individualized ^[1]. No such exception exists for a drug that has never been approved ^[1].

The practical consequence for consumers is that any retatrutide sold through a website, clinic or pharmacy sits outside the regulatory system entirely — no FDA review of its identity, purity or dose, and no approved labeling ^[1]. Frier Levitt also warns that an RUO label is not a legal shield, and that dosing charts, injection instructions and weight-loss claims can be used as evidence a product was never intended for research ^[1].

What happens next

The six Texas cases are pending, and Lilly seeks permanent injunctions in each ^[1]. A second open question is regulatory: Lilly has challenged the FDA's determination that retatrutide is a biological product, and a federal court has vacated and remanded part of that decision on whether the molecule is "analogous" to a protein ^[1]. If retatrutide is ultimately licensed as a biologic under Section 351 of the Public Health Service Act, the drug-compounding exemptions in Sections 503A and 503B would not offer a compounding pathway even after approval ^[1]. Lilly's FDA submission is not expected before 2027, and no approval date is known ^[1].